CD19 and diffuse large B-cell lymphoma: Axicabtagene ciloleucel, also known as KTE-C19, Axi-Cel, or Yescarta, is the second approved CD19-targeted second-generation CAR-T-cell therapy used for adult patients with large B-cell lymphomas (primary mediastinal large B-cell lymphomas, HGBCL, including DLBCL, not otherwise specified); it received approval by the FDA on 18 October 2017 and was made commercially available by Kite Pharma [122].